Viking Therapeutics, Inc. — Director's Dealing 2023

Apr 4, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Viking Therapeutics, Inc. (VKTX)
CIK: 0001607678
Period of Report: 2023-03-30

Reporting Person: ZANTE GREG (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-03-30	Common Stock, par value $0.00001 per share	M	32000	$8.52	Acquired	217057	Direct
2023-03-30	Common Stock, par value $0.00001 per share	M	42000	$7.69	Acquired	259057	Direct
2023-03-30	Common Stock, par value $0.00001 per share	M	12250	$4.65	Acquired	271307	Direct
2023-03-30	Common Stock, par value $0.00001 per share	M	7500	$4.12	Acquired	278807	Direct
2023-03-30	Common Stock, par value $0.00001 per share	S	131029	$17.0025	Disposed	147778	Direct
2023-04-03	Common Stock, par value $0.00001 per share	M	30911	$7.77	Acquired	178689	Direct
2023-04-03	Common Stock, par value $0.00001 per share	S	30911	$18.00	Disposed	147778	Direct
2023-04-03	Common Stock, par value $0.00001 per share	A	56667	$0.00	Acquired	204445	Direct
2023-04-03	Common Stock, par value $0.00001 per share	F	55166	$17.57	Disposed	149279	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-03-30	Stock Option (right to buy)	$8.52	M	32000	Disposed	2029-01-15	Common Stock (32000)	Direct
2023-03-30	Stock Option (right to buy)	$7.69	M	42000	Disposed	2029-07-31	Common Stock (42000)	Direct
2023-03-30	Stock Option (right to buy)	$4.65	M	12250	Disposed	2028-01-19	Common Stock (12250)	Direct
2023-03-30	Stock Option (right to buy)	$4.12	M	7500	Disposed	2028-04-30	Common Stock (7500)	Direct
2023-04-03	Stock Option (right to buy)	$7.77	M	30911	Disposed	2030-01-03	Common Stock (30911)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person.

F2: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2022, 66.67% of which vested on April 3, 2023 upon the achievement of two non-financial performance goals.

F3: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units.

F4: 25% of the shares subject to the option vested on each one year anniversary of the grant date.

F5: One-third of the shares subject to the option vested on each one year anniversary of the grant date.

F6: 25% of the shares subject to the option vested upon grant and 25% of the shares subject to the option vested on each one year anniversary of the grant date.